← All diseases
Cancer
Lung cancer (non-small cell)
Do you want to receive a message when there is new research on Lung cancer (non-small cell)? This is possible with an account. Create a free account or log in.
Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence
Read in plain language what each study is about? With Premium, one sentence appears above each publication explaining what was studied — and you'll be notified as soon as new research about Lung cancer (non-small cell) is available. View what Premium costs.
Publications and studies (3220)
- Commentary or editorialiAn expert's opinion or commentary, not new research. Neoadjuvant Chemotherapy with Low-Dose Nivolumab Leading to Complete Pathological Response in Non-small Cell Lung Carcinoma. (2025/06/01) ♡
- Ampelopsis japonica enhances the effect of radiotherapy in non-small cell lung cancer. (2025/06/01) ♡
- Jatrorrhizine Exhibits an Antitumor Effect Against Gefitinib-resistant Non-small Cell Lung Cancer via Inhibiting PI3K/mTOR Phosphorylation. (2025/06/01) ♡
- Albumin-myosteatosis gauge as a prognostic biomarker in patients treated with immune checkpoint inhibitors. (2025/06/01) ♡
- The inhibitory effects of modified HSJZ decoction on NSCLC by regulating regulatory T cells via downregulation of EZH2 and PI3K/AKT pathway. (2025/05/28) ♡
- Integrating network pharmacology and multi-omics to explore the potentiating effect and mechanism of Shenlingcao oral liquid on cisplatin chemotherapy in Lewis lung cancer mice. (2025/05/28) ♡
- Dynamic Alteration of HALP Score as a Predictor in Patients with Receiving Immunotherapy for Advanced Non-Small Cell Lung Cancer. (2025/05/27) ♡
- Biportal robotic-assisted surgery for lung segmentectomies: a surgical technique overview. (2025/05/27) ♡
- An attenuated coxsackievirus B5 mutant carrying VP1-N157K retains oncolytic potency against non-small cell lung cancer. (2025/05/23) ♡
- Variogram Modeling of Spatially Variant Early Response to Therapy in Advanced Non-Small Cell Lung Cancer. (2025/05/22) ♡
- Associated factors, emergency department visits, and hospitalization days of receiving adjunctive Chinese herbal medicine therapy for patients with non-small cell lung cancer: a nationwide cohort study in Taiwan. (2025/05/20) ♡
- Prolonged progression-free survival on epidermal growth factor receptor-tyrosine kinase inhibitors predicts superior response to atezolizumab-based therapy over chemotherapy in epidermal growth factor receptor-mutated non-small-cell lung cancer following progression. (2025/05/20) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Model-Based Evaluation of HangAmDan-B1 and Afatinib Combination Therapy in HCC827 Xenograft Mice with Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. (2025/05/19) ♡
- Clinical applications of deep learning in distinguishing benign from malignant pulmonary nodules in computed tomography scans. (2025/05/18) ♡
- Histologic Grade 3 in Stage 1A Lung Adenocarcinoma: Survival Risks Comparable to Stage 1B. (2025/05/15) ♡
- Combining network pharmacology and transcriptomics to validate and explore the efficacy and mechanism of Huayu Wan in treating non-small cell lung cancer. (2025/05/12) ♡
- Network pharmacology study on the mechanism of Curcumae Rhizoma in the treatment of non-small cell lung cancer. (2025/05/09) ♡
- Prognostic score models for acquired resistance to frontline anti-programmed cell death protein 1/programmed death-ligand 1 therapy in metastatic non-small-cell lung cancer. (2025/05/08) ♡
- Guiqi Baizhu decoction enhances radiosensitivity in non-small cell lung cancer by inhibiting the HIF-1α/DNA-PKcs axis-mediated DNA repair. (2025/05/01) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. SH003 Inhibits Proliferation and Induces Apoptosis in NSCLC Cell Lines by Inhibiting the Receptor Tyrosine Kinase-related Pathway. (2025/05/01) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Efficacy of Anlotinib Plus Docetaxel in Advanced NSCLC Previously Treated with Platinum-Based Chemotherapy: A Systematic Review and Meta-Analysis. (2025/04/29) ♡
- Feasibility and Safety of Anlotinib Plus Docetaxel versus Docetaxel Monotherapy in Patients with Previously Immunotherapy-Treated NSCLC: A Retrospective Exploratory Study. (2025/04/28) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The potential of natural herbal plants in the treatment and prevention of non-small cell lung cancer: An encounter between ferroptosis and mitophagy. (2025/04/25) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. New advances of natural products in non-small cell lung cancer: From mechanisms to therapies. (2025/04/25) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. New advances in the treatment of EGFR exon20ins mutant advanced NSCLC. (2025/04/25) ♡
- An Inhaled Nanoemulsion Encapsulating a Herbal Drug for Non-Small Cell Lung Cancer (NSCLC) Treatment. (2025/04/22) ♡
- Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Synergizing Success: The Role of Anlotinib Combinations in Advanced Non-Small Cell Lung Cancer Treatment. (2025/04/16) ♡
- Comparative effectiveness of immunotherapeutic regimens for untreated advanced non-small-cell lung cancer in real-world clinical practice: a Japanese cancer registry cohort study. (2025/04/14) ♡
- Combined Immune Checkpoint Blockade and Helixor (®) Therapy in Oncology: Real-World Tolerability and Subgroup Survival (ESMO GROW). (2025/04/12) ♡
- Validation of the EORTC QLQ-C30 questionnaire in its Tunisian version. (2025/04/05) ♡
- NRI and SIRI are the optimal combinations for prognostic risk stratification in patients with non-small cell lung cancer after EGFR-TKI therapy. (2025/04/01) ♡
- Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Combined large cell neuroendocrine carcinoma of the lung: case report with brief review. (2025/04/01) ♡
- Exploring the anti-NSCLC mechanism of phillyrin targeting inhibition of the HSP90-AKT pathway. (2025/04/01) ♡
- Proteomic screening identifies brusatol targets TGFβRII to suppresses non-small cell lung cancer metastasis. (2025/04/01) ♡
- N-Glycosylation Modification of Fzd4 Is Essential for the FZD4-Wnt-β-Catenin Signalling Axis. (2025/04/01) ♡
- Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Electroacupuncture for acute postoperative pain during coughing after video-assisted thoracoscopic surgery: study protocol for a pilot randomized controlled trial. (2025/03/26) ♡
- Study on the Material Basis and Mechanisms of Achyrocline satureioides in the Treatment of Nonsmall Cell Lung Cancer Based on Network Pharmacology and Spatial Metabolomics. (2025/03/18) ♡
- Design and Synthesis of Unsymmetric Benzils, Quinoxalines, and Evaluations of their Anticancer Activities against Human Non-Small Lung Cancer Cells. (2025/03/15) ♡
- Laboratory or animal researchiNo research in humans yet. Promising in a test tube or in mice unfortunately means nothing for patients. Multi-tissue metabolomics and network pharmacology study on the intervention of Danggui Buxue Decoction in mice with gemcitabine induced myelosuppression. (2025/03/13) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Editorial: KRAS in stage IV non-small cell lung cancer. (2025/03/10) ♡
- Definitions, measurement, and reporting of progression-free survival in randomized clinical trials and observational studies of patients with advanced non-small-cell lung cancer treated with immunotherapy: a scoping review. (2025/03/05) ♡
- The effect of environmental stressors on the anticancer potential of Amaranthus hypochondriacus aqueous extracts and fractions. (2025/03/01) ♡
- Analysis of postoperative weight loss associated with prognosis after sublobar resections for lung cancer. (2025/03/01) ♡
- Evaluation of nutritional parameters that may be associated with survival in patients with locally advanced non-small cell lung carcinoma receiving definitive concurrent chemoradiotherapy: retrospective study conducted in a tertiary pulmonary hospital. (2025/03/01) ♡
- Commentary or editorialiAn expert's opinion or commentary, not new research. Comment on: Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: A systematic literature review and meta-analysis of real-world evidence. (2025/03/01) ♡
- Clinical characteristics and prognostic analysis of patients with SMARCA4-deficient lung cancer. (2025/03/01) ♡
- Basic as a binding stabilizer of microRNA-145-5p suppresses the growth of non-small cell lung cancer. (2025/03/01) ♡
- Racialized economic segregation and disparities in non-small cell lung cancer care and outcomes. (2025/03/01) ♡
- Tanreqing suppresses the proliferation and migration of non-small cell lung cancer cells by mediating the inactivation of the HIF1α signaling pathway via exosomal CIRC-WDR78. (2025/03/01) ♡
- [Guiqi Yiyuan Ointment combined with cisplatin inhibits tumor growth in Lewis lung carcinoma-bearing mice by regulating PERK/eIF2α/ATF4/CHOP signaling pathway]. (2025/03/01) ♡
codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.